9 February 2021 - Late treatment study
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease (ORCHID)
et al., NCT04332991 (Preprint)
Late stage (65% on oxygen at baseline) low-dose RCT, not showing significant differences with treatment.
|
risk of death, 6.2% higher, RR 1.06, p = 0.85, treatment 25 of 241 (10.4%), control 25 of 236 (10.6%), NNT 455, adjusted per study, odds ratio converted to relative risk, day 28.
|
|
risk of death, 51.0% higher, RR 1.51, p = 0.28, treatment 18 of 241 (7.5%), control 14 of 236 (5.9%), adjusted per study, odds ratio converted to relative risk, day 14.
|
|
risk of 7-point scale, 3.1% higher, RR 1.03, p = 0.87, treatment 241, control 236, day 28, RR approximated with OR.
|
|
risk of 7-point scale, 2.0% lower, RR 0.98, p = 0.91, treatment 241, control 236, day 14, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Thompson et al., 2/9/2021, Double Blind Randomized Controlled Trial, USA, North America, preprint, 1 author.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.